IDSA : View All FDA Alerts

Print

ShareThis
Text Size

View All FDA Alerts
Search More FDA
02/27/2012
FDA Approves First H. pylori Breath Test for Children
FDA Alert
01/04/2012
FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older
FDA Alert
11/18/2011
FDA Approves First Supplemental Test for Chagas Disease
FDA Alert
10/25/2011
Xigris [drotrecogin alfa (activated)]: Market Withdrawal - Failure to Show Survival Benefit
FDA Alert
09/28/2011
FDA Clears First Single Use Face Mask for Children
FDA Alert
09/13/2011
FDA Investigates Multistate Outbreak of Listeriosis
FDA Alert
09/08/2011
Tumor Necrosis Factor-alpha Blockers: Label Change - Boxed Warning Updated for Risk of Infection from Legionella and Listeria
FDA Alert
08/03/2011
Diflucan (fluconazole): Long-term, High-dose Use During Pregnancy May Be Associated With Birth Defects
FDA Alert
07/26/2011
Zyvox (linezolid): Drug Safety Communication - Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications
FDA Alert
Approval changes to the Kaletra label
FDA Alert
FDA approves a second vaccine to prevent serogroup B meningococcal disease
FDA Alert
Don't Inject Patients with IV solutions from Wallcur
FDA Alert - updated 1/14/15
FDA approves new antibacterial drug Zerbaxa
FDA Alert
FDA approves Viekira Pak to treat hepatitis C
FDA Alert
Dietary Supplements Containing Live Bacteria or Yeast in Immunocompromised Persons: Warning - Risk of Invasive Fungal Disease
FDA Alert
FDA approves Gardasil 9 for prevention of HPV
FDA Alert
First vaccine approved by FDA to prevent serogroup B Meningococcal disease
FDA Alert
Cubist Pharmaceuticals Issues Voluntary U.S. Recall Of Certain Lots Of CUBICIN
FDA Alert
FDA approves Orbactiv to treat skin infections
FDA Alert
FDA Approves Sivextro to Treat Skin Infections
FDA Alert
HIV/AIDS Update - Revised HHS Adult and Adolescent Antiretroviral Treatment Guidelines available
FDA Alert
FDA approves new treatment for hepatitis C virus
IDSA Continues to Recommend Antivirals for Influenza
IDSA continues to recommend the use of neuraminidase inhibitor antiviral drugs in the treatment of influenza.
Alert: FDA Statement about Product Quality of Parenteral Vancomycin Products
Drug Interactions: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs
FDA Alert
Drug Safety Communication: Statins and HIV or Hepatitis C Drugs - Interaction Increases Risk of Muscle Injury (Content)
FDA Alert
Drug Safety: Clostridum difficle-Associated Diarrhea Can Be Associated with Proton Pump Inhibitors (PPIs)
FDA Alert
Facts about Victrelis (boceprevir) and HIV protease inhibitors
Facts about Victrelis (boceprevir) and HIV protease inhibitors Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines peginterferon alfa and ribavirin to treat chronic (long lasting) hepatitis C infection in adults who have not
FDA Safety Communication: Risk of Bacterial Contamination with Other-Sonic Generic Ultrasound Transmission Gel
FDA Statement about Product Quality of Parenteral Vancomycin Products
FDA Alert
Zithromax (azithromycin): FDA Statement on risk of cardiovascular death
FDA Approves New Combination Pill for HIV Treatment for Some Patients
FDA Alert
Updates on Fungal Meningitis Outbreak
FDA Alert
FDA Statement on Fungal Meningitis Outbreak
FDA Alert
FDA Reposts NECC Customer List
FDA Alert
Update on NECC Products: Samples of Betamethasone and Cardioplegia Solution Test Positive for Bacter(1)
FDA Alert
FDA Approves First Drug to Treat Multi-Drug Resistant Tuberculosis
FDA Alert
FDA Approves First Anti-Diarrheal Drug for HIVAIDS Patients
FDA Alert
FDA Approves New Seasonal Influenza Vaccine Made Using Novel Technology
FDA Alert
FDA Expands Tamiflu’s Use to Treat Children Younger Than 1 Year
FDA Alert
Serious Skin Reactions After Combination Treatment with the Hepatitis C Drugs Incivek Telaprevir, Peginterferon Alfa, and Ribavirin
FDA Alert
Drug Information Update - FDA Approves Raxibacumab to Treat Inhalational Anthrax
FDA Alert
FDA Approves TOBI Podhaler to Treat a Type of Bacterial Lung Infection in Cystic Fibrosis Patients
FDA Alert
Drug Recall: BIVIGAM Immune Globulin Intravenous Human, 10 Percent Liquid, 100 mL Sterile Vial
FDA Alert
FDA Announces Voluntary Nationwide Recall by Balanced Solutions Compounding Pharmacy
FDA Alert
FDA Recall: Piperacillin and Tazobactam for Injection, USP 40.5 grams - Precipitation or Crystallization in IV Bag or IV Line Upon Reconstitution
FDA Alert
In Cooperation with FDA, The Compounding Shop, LLC Declares a Voluntary Recall of All Lots of Sterile Compounded Products Due to a Lack of Sterility Assurance Distributed Within its Local Market Area
FDA Alert
Main Street Family Pharmacy, LLC Issues Voluntary Nationwide Recall of All Sterile Compounded Products
FDA Alert
Olympia Pharmacy Sterile Compounded Products: Recall - Concerns About Sterility Assurance
FDA Alert
Update on Main Street Family Pharmacy Products: Samples of Injectable Methylprednisolone Acetate Test Positive for Microbial Contamination
FDA Alert

Subscribe for Updates

Average 0 out of 5

| HIVMA | Contact Us

© Copyright IDSA 2015 Infectious Diseases Society of America

Full Site Mobile Site